Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

PURPOSE: To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine. PATIENTS AND METHODS: Eligible adults (advanced solid tumor; performance status ≤ 2) received capecitabine 500mg/m(2) PO BID days 1-14 and FDR gemcitabine (...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Attia, Steven, Morgan-Meadows, Sherry, Holen, Kyle D., Bailey, Howard H., Eickhoff, Jens C., Schelman, William R., Traynor, Anne M., Mulkerin, Daniel L., Campbell, Toby C., McFarland, Thomas A., Huie, Michael S., Cleary, James F., Tevaarwerk, Amye J., Alberti, Dona B., Wilding, George, Liu, Glenn
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676212/
https://ncbi.nlm.nih.gov/pubmed/18841362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0844-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky